Lifecore Biomedical, Inc. \De\ (NASDAQ: LFCR)

Lifecore Biomedical, Inc. \De\ operates as a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, cGMP manufacturing, and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products. The company is a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) using its proprietary, fermentation-based HA process developed in 1981. Lifecore's expertise extends to the manufacturing of HA in bulk form and for use in formulated and filled syringes and vials for injectable products addressing a broad spectrum of medical conditions and procedures, including ophthalmic and orthopedic applications. Additionally, the company leverages its HA fermentation, manufacturing, and aseptic formulation and filling expertise to develop highly viscous non-HA-based sterile injectable products for multiple applications.

Lifecore generates revenue through its comprehensive service offerings, which include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company operates semi-automated Restricted Access Barrier Systems (RABS) and fully automated aseptic filling lines with isolators, supporting efficient and safe aseptic processing of both synthetic and biologic drug products. Manufacturing occurs across three cGMP facilities, producing FDA-approved commercial drug and device products. Lifecore has earned multiple certifications from regulatory agencies in Europe, Japan, Brazil, and the International Organization for Standardization (ISO). The company's primary customer base consists of global and emerging biopharmaceutical and biotechnology companies with marketing, sales, and distribution capabilities across multiple therapeutic categories.

• CDMO and HA Manufacturing: Lifecore's core segment involves the development, manufacturing, and aseptic filling of complex formulations and highly viscous sterile injectable products. The company's proprietary fermentation-based HA process is central to this segment, catering to the pharmaceutical and medical device industries. Lifecore's capabilities extend to non-HA-based sterile injectable products, addressing a wide range of medical applications. The segment leverages advanced manufacturing technologies, including semi-automated RABS and fully automated aseptic filling lines, to ensure high-quality production. This segment serves biopharmaceutical and biotechnology companies seeking reliable manufacturing partners for their injectable products.

Lifecore Biomedical, Inc. \De\ holds a strong position within the contract development and manufacturing industry, characterized by intense competition and stringent regulation. The company's competitive advantages include strong relationships with market leaders, the ability to expand medical applications for HA, manufacturing capabilities and expertise with respect to highly complex and viscous injectables, vertically integrated CDMO capabilities, and regulatory and quality expertise. Lifecore has established long-term relationships with global and emerging biopharmaceutical and biotechnology companies, some spanning nearly 40 years. The company's strategic capital investments in aseptic filling capacity and capabilities, particularly the installation of a new fully automated high-speed, multi-purpose 5-head aseptic isolator filler in September 2024, have significantly expanded its available capacity and range of project opportunities. Lifecore's vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with customers globally, extending from supplying HA raw materials to providing technology transfer and development services to manufacturing aseptically filled, finished sterile injectable products. The company's strong multi-compendial quality and regulatory system, demonstrated by its over 40-year track record with global regulatory bodies, positions it as a trusted partner for companies seeking proven experience in delivering QbD, cGMP compliance, and manufacturing excellence.

Lifecore's customer base comprises global and emerging biopharmaceutical and biotechnology companies with marketing, sales, and distribution capabilities across multiple therapeutic categories. The company's long-standing relationships with these customers, some of which have lasted for decades, underscore its reputation and reliability in the industry. Lifecore's strategic initiatives to support higher performance as a CDMO, including significant improvements to its revenue-generating capacity, financial position, management team, governance, financial reporting, and stock exchange compliance, further enhance its appeal to potential and existing customers. The company's focus on expanding its target market to include large multinational pharmaceutical companies and capitalizing on investments in technology and creating a more agile organization supports its efforts to attract new business and drive growth.